Expression of breast cancer resistance protein is associated with a poor clinical outcome in patients with small-cell lung cancer

Lung Cancer

Volumn 65, Issue 1, 2009, Pages 105-111

  Kim, Young Hak ^a,b   Ishii, Genichiro ^a   Goto, Koichi ^a   Ota, Shuji ^a   Kubota, Kaoru ^a   Murata, Yukinori ^a   Mishima, Michiaki ^b   Saijo, Nagahiro ^a   Nishiwaki, Yutaka ^a   Ochiai, Atsushi ^a  

^a NATIONAL CANCER CENTER HOSPITAL EAST   (Japan)

^b KYOTO UNIVERSITY HOSPITAL   (Japan)

Author keywords

ABC transporter; BCRP; DNA excision repair; MDR; SCLC

Indexed keywords

ABC TRANSPORTER; BRCA1 PROTEIN; BREAST CANCER RESISTANCE PROTEIN; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 1; GLYCOPROTEIN P; IRINOTECAN; MULTIDRUG RESISTANCE PROTEIN 1; MULTIDRUG RESISTANCE PROTEIN 2; MULTIDRUG RESISTANCE PROTEIN 3; PLATINUM; TOPOTECAN; VINCRISTINE;

ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL ASSESSMENT; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; PRIORITY JOURNAL; PROTEIN EXPRESSION; TREATMENT RESPONSE; TUMOR BIOPSY;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ATP-BINDING CASSETTE TRANSPORTERS; BIOPSY; CARCINOMA, NON-SMALL-CELL LUNG; DNA-BINDING PROTEINS; ENDONUCLEASES; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LUNG NEOPLASMS; MALE; MIDDLE AGED; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; MULTIVARIATE ANALYSIS; NEOPLASM PROTEINS; P-GLYCOPROTEIN; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 67349169090     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lungcan.2008.10.008     Document Type: Article

References (39)

1. Thatcher N., Faivre-Finn C., and Lorigan P. Management of small-cell lung cancer. Ann Oncol 16 Suppl 2 (2005) ii235-ii239
2. Leonard G.D., Fojo T., and Bates S.E. The role of ABC transporters in clinical practice. Oncologist 8 5 (2003) 411-424
3. Ozben T. Mechanisms and strategies to overcome multiple drug resistance in cancer. FEBS Lett 580 12 (2006) 2903-2909
4. Szakacs G., Paterson J.K., Ludwig J.A., Booth-Genthe C., and Gottesman M.M. Targeting multidrug resistance in cancer. Nat Rev Drug Discov 5 3 (2006) 219-234
5. Rosell R., Cobo M., Isla D., Sanchez J.M., Taron M., Altavilla G., et al. Applications of genomics in NSCLC. Lung Cancer 50 Suppl 2 (2005) S33-S40
6. Olaussen K.A., Dunant A., Fouret P., Brambilla E., André F., Haddad V., et al. DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med 355 10 (2006) 983-991
7. Furuta T., Ueda T., Aune G., Sarasin A., Kraemer K.H., and Pommier Y. Transcription-coupled nucleotide excision repair as a determinant of cisplatin sensitivity of human cells. Cancer Res 62 17 (2002) 4899-4902
8. Pujol J.L., Carestia L., and Daures J.P. Is there a case for cisplatin in the treatment of small-cell lung cancer? A meta-analysis of randomized trials of a cisplatin-containing regimen versus a regimen without this alkylating agent. Br J Cancer 83 1 (2000) 8-15
9. Noda K., Nishiwaki Y., Kawahara M., Negoro S., Sugiura T., Yokoyama A., et al. Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer. N Engl J Med 346 2 (2002) 85-91
10. Hanna N., Bunn Jr. P.A., Langer C., Einhorn L., Guthrie Jr. T., Beck T., et al. Randomized phase III trial comparing irinotecan/cisplatin with etoposide/cisplatin in patients with previously untreated extensive-stage disease small-cell lung cancer. J Clin Oncol 24 13 (2006) 2038-2043
11. Zelen M. Keynote address on biostatistics and data retrieval. Cancer Chemother Rep 3 4 2 (1973) 31-42
12. Therasse P., Arbuck S.G., Eisenhauer E.A., Wanders J., Kaplan R.S., Rubinstein L., et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92 3 (2000) 205-216
13. Filipits M., Haddad V., Schmid K., Huynh A., Dunanat A., André F., et al. Multidrug resistance proteins do not predict benefit of adjuvant chemotherapy in patients with completely resected non-small cell lung cancer: International Adjuvant Lung Cancer Trial Biologic Program. Clin Cancer Res 13 13 (2007) 3892-3898
14. Wachters F.M., Wong L.S., Timens W., Kampinga H.H., and Groen H.J. ERCC1, hRad51, and BRCA1 protein expression in relation to tumour response and survival of stage III/IV NSCLC patients treated with chemotherapy. Lung Cancer 50 2 (2005) 211-219
15. Spiro S.G., and Silvestri G.A. One hundred years of lung cancer. Am J Respir Crit Care Med 172 5 (2005) 523-529
16. Haimeur A., Conseil G., Deeley R.G., and Cole S.P. The MRP-related and BCRP/ABCG2 multidrug resistance proteins: biology, substrate specificity and regulation. Curr Drug Metab 5 1 (2004) 21-53
17. Allen J.D., and Schinkel A.H. Multidrug resistance and pharmacological protection mediated by the breast cancer resistance protein (BCRP/ABCG2). Mol Cancer Ther 1 6 (2002) 427-434
18. Yoh K., Ishii G., Yokose T., Minegishi Y., Tsuta K., Goto K., et al. Breast cancer resistance protein impacts clinical outcome in platinum-based chemotherapy for advanced non-small cell lung cancer. Clin Cancer Res 10 5 (2004) 1691-1697
19. Savaraj N., Wu C.J., Xu R., Lampidis T., Lai S., Donnelly E., et al. Multidrug-resistant gene expression in small-cell lung cancer. Am J Clin Oncol 20 4 (1997) 398-403
20. Kawasaki M., Nakanishi Y., Kuwano K., Takayama K., Kiyohara C., and Hara N. Immunohistochemically detected p53 and P-glycoprotein predict the response to chemotherapy in lung cancer. Eur J Cancer 34 9 (1998) 1352-1357
21. Hsia T.C., Lin C.C., Wang J.J., Ho S.T., and Kao A. Relationship between chemotherapy response of small cell lung cancer and P-glycoprotein or multidrug resistance-related protein expression. Lung 180 3 (2002) 173-179
22. Yeh J.J., Hsu N.Y., Hsu W.H., Tsai C.H., Lin C.C., and Liang J.A. Comparison of chemotherapy response with P-glycoprotein, multidrug resistance-related protein-1, and lung resistance-related protein expression in untreated small cell lung cancer. Lung 183 3 (2005) 177-183
23. Triller N., Korosec P., Kern I., Kosnik M., and Debeljak A. Multidrug resistance in small cell lung cancer: expression of P-glycoprotein, multidrug resistance protein 1 and lung resistance protein in chemo-naive patients and in relapsed disease. Lung Cancer 54 2 (2006) 235-240
24. Milroy R. A randomised clinical study of verapamil in addition to combination chemotherapy in small cell lung cancer. West of Scotland Lung Cancer Research Group, and the Aberdeen Oncology Group. Br J Cancer 68 4 (1993) 813-818
25. Wood L., Palmer M., Hewitt J., Urtasun R., Bruera E., Rapp E., et al. Results of a phase III, double-blind, placebo-controlled trial of megestrol acetate modulation of P-glycoprotein-mediated drug resistance in the first-line management of small-cell lung carcinoma. Br J Cancer 77 4 (1998) 627-631
26. Gandhi L., Harding M.W., Neubauer M., Langer C.J., Moore M., Ross H.J., et al. A phase II study of the safety and efficacy of the multidrug resistance inhibitor VX-710 combined with doxorubicin and vincristine in patients with recurrent small cell lung cancer. Cancer 109 5 (2007) 924-932
27. Lee H.W., Han J.H., Kim J.H., Lee M.H., Jeong S.H., Kang S.Y., et al. Expression of excision repair cross-complementation group 1 protein predicts poor outcome in patients with small cell lung cancer. Lung Cancer 59 1 (2008) 95-104
28. Lord R.V., Brabender J., Gandara D., Alberola V., Camps C., Domine M., et al. Low ERCC1 expression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in non-small cell lung cancer. Clin Cancer Res 8 7 (2002) 2286-2291
29. Takenaka T., Yoshino I., Kouso H., Ohba T., Yohena T., Osoegawa A., et al. Combined evaluation of Rad51 and ERCC1 expressions for sensitivity to platinum agents in non-small cell lung cancer. Int J Cancer 121 4 (2007) 895-900
30. Taron M., Rosell R., Felip E., Mendez P., Souglakos J., Ronco M.S., et al. BRCA1 mRNA expression levels as an indicator of chemoresistance in lung cancer. Hum Mol Genet 13 20 (2004) 2443-2449
31. Booton R., Ward T., Ashcroft L., Morris J., Heighway J., and Thatcher N. ERCC1 mRNA expression is not associated with response and survival after platinum-based chemotherapy regimens in advanced non-small cell lung cancer. J Thorac Oncol 2 10 (2007) 902-906
32. Dean M., Fojo T., and Bates S. Tumour stem cells and drug resistance. Nat Rev Cancer 5 4 (2005) 275-284
33. Hadnagy A., Gaboury L., Beaulieu R., and Balicki D. SP analysis may be used to identify cancer stem cell populations. Exp Cell Res 312 19 (2006) 3701-3710
34. Mao Q., and Unadkat J.D. Role of the breast cancer resistance protein (ABCG2) in drug transport. Aaps J 7 1 (2005) E118-E133
35. Ho M.M., Ng A.V., Lam S., and Hung J.Y. Side population in human lung cancer cell lines and tumors is enriched with stem-like cancer cells. Cancer Res 67 10 (2007) 4827-4833
36. Rabindran S.K., Ross D.D., Doyle L.A., Yang W., and Greenberger L.M. Fumitremorgin C reverses multidrug resistance in cells transfected with the breast cancer resistance protein. Cancer Res 60 1 (2000) 47-50
37. Robey R.W., Steadman K., Polgar O., Morisaki K., Blayney M., Mistry P., et al. Pheophorbide a is a specific probe for ABCG2 function and inhibition. Cancer Res 64 4 (2004) 1242-1246
38. Minderman H., O'Loughlin K.L., Pendyala L., and Baer M.R. VX-710 (biricodar) increases drug retention and enhances chemosensitivity in resistant cells overexpressing P-glycoprotein, multidrug resistance protein, and breast cancer resistance protein. Clin Cancer Res 10 5 (2004) 1826-1834
39. Qadir M., O'Loughlin K.L., Fricke S.M., Williamson N.A., Greco W.R., Minderman H., et al. Cyclosporin A is a broad-spectrum multidrug resistance modulator. Clin Cancer Res 11 6 (2005) 2320-2326